A “receptor-negative” or “triple negative” category refers to cancers that lack the expression of three receptor proteins, namely, PgR, ER, and ERBB2 receptors.17 This breast cancer subtype makes up about 10–15% of breast cancer cases and is regarded as one of the most extensively proliferative and aggressive types of cancer with poor prognosis.18,19 Currently, standard chemotherapy is the only management option in the case of triple negative cancer.19 Chemotherapy together with taxanes namely paclitaxel and docetaxel are very efficient cytotoxic agents. The gene discussed is ESR1; the disease is breast cancer.